You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,680,068


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,680,068
Title: Drug delivery formulations and targeting
Abstract:The invention is based on the discovery that angiogenic vessels have heterogeneous surface charge and that cationic liposomes actually target human tumor blood vessels only in irregularly shaped patches. The invention thus features methods for delivering therapeutic compounds to angiogenic vascular endothelial surfaces using a mixture, or \"cocktail\", of positively charged and neutral liposomes. The new methods can be used to target multiple regions on the same tumor vessel and/or clusters of vessels within the same tumor. Liposomes with different chemical and/or physical properties (e.g., charge, stability, solubility, diameter) can be delivered simultaneously, and can target tumor vessels and other angiogenic vessels with greater efficiency compared to cationic liposomes alone.
Inventor(s): Campbell; Robert B. (Boston, MA), Jain; Rakesh K. (Boston, MA)
Assignee: The General Hospital Corporation (Boston, MA)
Application Number:09/898,107
Patent Claims:1. A formulation comprising: cationic liposomes comprising a first therapeutic agent, and electrostatically neutral liposomes comprising a second therapeutic agent, wherein the first and second therapeutic agents can be the same or different.

2. The formulation of claim 1, wherein the ratio of cationic liposomes to neutral liposomes is between 1:9 and 9:1.

3. The formulation of claim 1, wherein the ratio of cationic liposomes to neutral liposomes is between 1:3 and 3:1.

4. The formulation of claim 1, wherein the ratio of cationic liposomes to neutral liposomes is between 2:3 and 3:2.

5. The formulation of claim 1, wherein at least one of the first and second therapeutic agents is an anti-tumor drug.

6. The formulation of claim 1, wherein at least one of the first and second therapeutic agents is a nucleic acid.

7. The formulation of claim 1, wherein the cationic liposomes comprise one or more lipids selected from the group consisting of dioleoyltrimethyl-ammonium propane (DOTAP), N-[1-(2,3-dioleoyloxy)-propyl]-N,N,N-triethylammonium chloride (DOTMA), dimethyldioctadecylammonium bromide (DDAB), 1,2-dimyristyloxypropyl-3-dimethylhydroxyethyl (DMRIE), dioleoyl-3-dimethylammonium propane (DODAP), N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), and N-(1-(2,3-dioleyloxy)-propyl)-N-(2-(sperminecarboxamido)ethyl)-N,N-dimethy l ammonium trifluoroacetate (DOSPA).

8. The formulation of claim 1, wherein at least one of the first and second therapeutic agents is selected from the group consisting of alkylating agents, plant alkaloids, antimetabolites, and antibiotic.

9. The formulation of claim 1, wherein the neutral liposomes comprise one or more lipids selected from the group consisting of dioleoylphosphatidyl-choline (DOPC), dipalmitoylphosphatidylcholine (DPPC), disteroylphosphatidylcholine (DSPC), dimyristoylphosphatidylcholine (DMPC), and 1,2-sn-dioleoylphosphatidylcholine (DOPE).

10. The formulation of claim 1, wherein at least one of the first and second therapeutic agents is selected from the group consisting of mechlorethamine hydrochloride, cyclophosphamide, ifosfamide, chlorambucil, melphalan, busulfan, thiotepa, carmustine, lomustine, and streptozocin.

11. The formulation of claim 1, wherein at least one of the first and second therapeutic agents is selected from the group consisting of vincristine, paclitaxel, vinblastine, vinorelbine, and docetaxel.

12. A The formulation of claim 1, wherein at least one of the first and second therapeutic agents is selected from the group consisting of methotrexate, mercaptopurine, thioguanine, fluorouracil, cytarabine, azacitidine, fludarabine, cladribine, and pentostatin.

13. The formulation of claim 1, wherein at least one of the first and second therapeutic agents is selected from the group consisting of dactinomycin, daunorubicin, doxorubicin, idarubicin, mitoxantrone, bleomycin, plicamycin, and mitomycin.

14. The formulation of claim 1, wherein at least one of the first and second therapeutic agents is selected from the group consisting of hydroxyurea, procarbazine, dacarbazine, cisplatin, carboplatin, asparaginase, etoposide, amsacrine, mitotane, topotecan, and tretinoin.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.